KPV Peptide: Anti-Inflammatory Mechanisms and Gut Health Research
KPV (Lys-Pro-Val) is a tripeptide fragment of α-MSH with potent anti-inflammatory properties. Research focuses on its application in IBD models, skin inflammation, and wound healing — often via oral or topical routes.
Dr. Elena Vasquez
Research Scientist
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH). Despite its small size — just three amino acids — KPV retains the core anti-inflammatory activity of the parent peptide while lacking its melanotropic (pigmentation-stimulating) effects. This selectivity has driven significant research interest in inflammatory bowel disease (IBD), skin disorders, and infection-driven inflammation.
Mechanism of Action
KPV exerts anti-inflammatory effects through several partially overlapping mechanisms:
- Melanocortin receptor (MCR) signalling: Binds MC1R and MC3R on immune cells, triggering cAMP-PKA signalling that suppresses NF-κB activation — the central transcription factor for pro-inflammatory cytokine production.
- Direct intracellular entry: Unusually for a peptide, KPV can cross cell membranes and directly inhibit NF-κB nuclear translocation, an effect shown in epithelial cell lines.
- Cytokine suppression: Demonstrated reductions in IL-1β, IL-6, TNF-α, and IL-8 across multiple inflammatory models.
- Intestinal epithelial barrier support: Upregulates tight junction proteins (occludin, ZO-1) in gut epithelial cells, potentially reducing permeability during inflammation.
IBD and Gut Research
KPV has been studied extensively in murine colitis models:
- Oral KPV in dextran sulfate sodium (DSS)-induced colitis mice significantly reduced colon inflammation scores, weight loss, and pro-inflammatory cytokine levels compared to controls.
- Nanoparticle-encapsulated oral KPV (to improve stability in the GI tract) showed enhanced efficacy versus free peptide in colonic delivery studies.
- Intraperitoneal KPV in IL-10-knockout mice (a chronic IBD model) attenuated spontaneous colitis development over 8-week treatment periods.
Researchers sourcing KPV peptide for gut inflammation studies should ensure lyophilised purity ≥98% to minimise confounding endotoxin effects.
Skin and Wound Applications
KPV's anti-inflammatory efficacy extends to dermatological research:
- Topical KPV reduces paw oedema and skin inflammation in carrageenan and arachidonic acid murine models.
- In psoriasis-like skin models, KPV normalises keratinocyte hyperproliferation and reduces inflammatory infiltrate.
- Wound healing studies show accelerated re-epithelialisation in KPV-treated wounds versus vehicle, attributed to both reduced inflammation and direct proliferative effects on fibroblasts.
Peptide Profile
| Property | Value |
|---|---|
| Sequence | Lys-Pro-Val |
| Molecular weight | 341.43 g/mol |
| Route (research) | Oral, topical, intraperitoneal, subcutaneous |
| Oral stability | Moderate; nanoparticle encapsulation improves GI delivery |
References
- Kannengiesser K, et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine experimental colitis. Inflammatory Bowel Diseases, 14(3), 324–331.
- Brzoska T, et al. (2008). Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo. Endocrine Reviews, 29(5), 581–602.
- Laroui H, et al. (2013). Targeting intestinal inflammation with nanoparticles loaded with KPV. Biomaterials, 34(33), 8521–8530.
